Voriconazole: A novel azole antifungal

Formulary

Volumn 37, Issue 8, 2002, Pages 387-398

  Florea, Naomi R ^a   Kuti, Joseph L ^a   Quintiliani, Richard ^a  

^a HARTFORD HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B; ANTIFUNGAL AGENT; CYCLOSPORIN; CYTOCHROME P450; FLUCONAZOLE; ITRACONAZOLE; OMEPRAZOLE; PHENYTOIN; RAPAMYCIN; RIFABUTIN; RIFAMPICIN; TACROLIMUS; TRIAZOLE DERIVATIVE; VORICONAZOLE; WARFARIN;

AREA UNDER THE CURVE; ASPERGILLOSIS; ASPERGILLUS; CANDIDA; CLINICAL TRIAL; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG INHIBITION; DRUG POTENTIATION; DRUG STRUCTURE; FUSARIUM; HUMAN; MINIMUM INHIBITORY CONCENTRATION; MYCOSIS; REVIEW; SCEDOSPORIUM APIOSPERMUM;

EID: 0036675637     PISSN: 1082801X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (28)

1. Trends in mortality due to invasive mycotic diseases in the United States, 1980-1997
2. Therapeutic outcome in invasive aspergillosis
3. Bloodstream infections due to Candida species: SENTRY antimicrobial surveillance program in North America and Latin American, 1997-1998
4. Trends in antifungal susceptibility of Candida spp. isolated from pediatric and adult patients with bloodstream infections: SENTRY antimicrobial surveillance program, 1997 to 2000
5. Review of the safety and efficacy of voriconazole
6. UK-109,496: A novel, wide-spectrum triazole derivative for the treatment of fungal infections: Discovery and antifungal properties
7. UK-109, 496, a novel, wide-spectrum triazole derivative for the treatment of fungal infection: Disposition in animals
8. Successful treatment of cerebral aspergillosis with a novel triazole (voriconazole) in a patient with acute leukaemia
9. Invasive aspergillosis caused by Aspergillus ustus: Case report and review
10. Evaluation of voriconazole pharmacodynamics using time-kill methodology
11. Comparative in vitro activity of voriconazole and itraconazole against fluconazole-susceptible and fluconazole-resistant clinical isolates of Candida species from Spain
12. International surveillance of bloodstream infections due to Candida species: Frequency of occurrence and in vitro susceptibilities to fluconazole, ravuconazole, and voriconazole of isolates collected from 1997 through 1999 in the SENTRY antimicrobial surveillance program
13. Azole resistance in Candida, Aspergillus and Penicillium species: Results of a three year Canadian national surveillance study
14. In vitro activities of voriconazole (UK-109,496) against fluconazole-susceptible and -resistant Candida albicans isolates from oral cavities of patients with Human Immunodeficiency Virus infection
15. Comparison of the in vitro activity of voriconazole (UK-109,496), itraconazole and amphotericin B against clinical isolates of Aspergillus fumigatus
16. A comparative study of the in vitro susceptibilities of clinical and laboratory-selected resistant isolates of Aspergillus spp. to amphotericin B, itraconazole, voriconazole and posaconazole (SCH 56592)
17. In vitro susceptibilities of Aspergillus species to voriconazole, itraconazole, and amphotericin B
18. In vitro comparative efficacy of voriconazole and itraconazole against fluconazole-susceptible and -resistant Cryptococcus neoformans isolates
19. In vitro activities of voriconazole, fluconazole, and itraconazole against 566 clinical isolates of Cryptococcus neoformans from the United States and Africa
20. A randomized, double-blind, double-dummy, multicenter trial of voriconazole and fluconazole in the treatment of esophageal candidiasis in immunocompromised patients
21. Voriconazole compared with liposomal amphotericin B for empirical antifungal therapy in patients with neutropenia and persistent fever
22. Efficacy and safety of voriconazole in the treatment of acute invasive aspergillosis
23. Visual effects of voriconazole (V)
24. Investigation of the relationship between plasma voriconazole concentrations and liver function tests abnormalities in therapeutic trials